netFormulary NHS
Ipswich and East Suffolk CCG
North East Essex CCG
East Suffolk and North East Essex NHS Foundation Trust
 Search
 Formulary Chapter 6: Endocrine system - Full Section
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
06.01 Drugs used in diabetes (0,0)
06.01.01 Insulins (0,0)
06.01.01.01 Short-acting insulins (3,7)
Soluble insulin (2,0)
Ultra-Rapid acting insulin analogues (1,0)
Short-acting human insulin analogues (2,0)
06.01.01.02 Intermediate- and long-acting insulins (9,7)
Biphasic insulins (4,3)
06.01.01.03 Hypodermic equipment (0,0)
Needles (2,0)
Lancets (1,0)
06.01.02 Antidiabetic drugs (0,0)
06.01.02.01 Sulphonyureas (3,5)
06.01.02.02 Biguanides (2,0)
06.01.02.03 Other antidiabetic drugs (0,14)
Alpha glucosidase inhibitors (0,0)
DPP4 inhibitors (gliptins) (4,0)
GLP1 agonists (6,0)
Meglitinides (1,0)
SGLT-2 inhibitors (4,0)
Thiazolidinediones (1,0)
06.01.03 Diabetic ketoacidosis (0,0)
06.01.04 Treatment of hypoglycaemia (4,1)
Chronic hypoglycaemia (1,0)
06.01.05 Treatment of diabetic nephropathy and neuropathy (0,0)
06.01.06 Diagnostic and monitoring agents for diabetes mellitus (0,0)
Oral glucose tolerance test (1,2)
Flash Glucose monitoring (1,0)
Blood glucose meters-all patients with Type 2 Diabetes and all patients with Type 1 (4,0)
Blood Ketone Meters Used in Type 1 Diabetes Only (2,0)
Higher-cost Test Strips that CAN ONLY BE PRESCRIBED IN SPECIFIC CIRCUMSTANCES (6,0)
Talking blood glucose meters (1,0)
06.02 Thyroid and Antithyroid drugs (0,0)
06.02.01 Thyroid hormones (3,1)
06.02.02 Antithyroid drugs (3,1)
06.03 Corticosteroids (0,0)
06.03.01 Replacement therapy (1,0)
06.03.02 Glucocorticoid therapy (12,3)
Disadvantages of corticosteroids (0,0)
Use of corticosteroids (0,0)
Pregnancy and breastfeeding (0,0)
Administration (0,0)
Withdrawal of corticosteroids (0,0)
06.04 Sex hormones (0,0)
06.04.01.01 Oestrogens and HRT (6,1)
Sequential combined (for women with uterus) (5,0)
Continuous combined (for women with uterus) (6,0)
Unopposed oestrogen (for women without uterus) (0,0)
Topical oestrogens (3,0)
Other (3,0)
06.04.01.02 Progestogens (2,0)
06.04.02 Male sex hormones and antagonists (5,0)
Anti-androgens (3,0)
06.04.03 Anabolic steroids (0,1)
06.04.04 Gender dysphoria (0,0)
06.05 Hypothalamic and pituitary hormones and anti-oestrogens (0,1)
06.05.01 Hypothalamic and anterior pituitary hormones and anti-oestrogens (1,1)
Anti-oestrogens (9,0)
Anterior pituitary hormones (9,4)
Hypothalmic hormones (2,0)
06.05.02 Posterior pituitary hormones and antagonists (1,0)
Posterior pituitary hormones (6,2)
Antidiuretic hormone antagonists (0,1)
06.06 Drugs affecting bone metabolism (0,0)
Osteoporosis (0,0)
06.06.01 Calcitonin and parathyroid hormone (2,0)
06.06.02 Bisphosphonates and other drugs affecting bone metabolism (0,1)
Bisphosphonates (8,4)
Denosumab (2,0)
Strontium renelate (0,1)
06.07 Other endocrine drugs (0,1)
06.07.01 Bromocriptine and other dopaminergic drugs (3,0)
06.07.02 Drugs affecting gonadotrophins (1,2)
Gonadorelin analogues (3,1)
Breast pain (mastalgia) (0,0)
06.07.03 Metyrapone (1,1)
06.07.04 Somatomedins (0,1)
netFormulary